Predictors of High Cardiovascular Risk Among Nonobese Patients with Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease in a Chinese Population

References

• Ahadi M, Molooghi K, Masoudifar N, Namdar AB, Vossoughinia H, Farzanehfar M. A review of non-alcoholic fatty liver disease in non-obese and lean individuals. J Gastroenterol Hepatol. 2021;36(6):1497–1507. doi:10.1111/jgh.15353
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84. doi:10.1002/hep.28431
   PubMed Web of Science ®Google Scholar
• Ye Q, Zou B, Yeo YH, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(8):739–752. doi:10.1016/S2468-1253(20)30077-7
   PubMed Web of Science ®Google Scholar
• Stefan N, Haring HU, Cusi K. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. Lancet Diabetes Endocrinol. 2019;7(4):313–324. doi:10.1016/S2213-8587(18)30154-2
   PubMed Web of Science ®Google Scholar
• Adams LA, Anstee QM, Tilg H, Targher G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut. 2017;66(6):1138–1153. doi:10.1136/gutjnl-2017-313884
   PubMed Web of Science ®Google Scholar
• Golabi P, Paik J, Fukui N, Locklear CT, de Avilla L, Younossi ZM. Patients with lean nonalcoholic fatty liver disease are metabolically abnormal and have a higher risk for mortality. Clin Diabetes. 2019;37(1):65–72. doi:10.2337/cd18-0026
   PubMedGoogle Scholar
• Ahmed OT, Gidener T, Mara KC, Larson JJ, Therneau TM, Allen AM. Natural history of nonalcoholic fatty liver disease with Normal Body Mass Index: a population-based study. Clin Gastroenterol Hepatol. 2022;20(6):1374–1381.e6. doi:10.1016/j.cgh.2021.07.016
   PubMed Web of Science ®Google Scholar
• Targher G, Bertolini L, Rodella S, et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care. 2007;30(8):2119–2121. doi:10.2337/dc07-0349
   PubMed Web of Science ®Google Scholar
• Nass KJ, van den Berg EH, Faber KN, Schreuder TCMA, Blokzijl H, Dullaart RPF. High prevalence of apolipoprotein B dyslipoproteinemias in non-alcoholic fatty liver disease: the lifelines cohort study. Metabolism. 2017;72:37–46. doi:10.1016/j.metabol.2017.04.004
   PubMed Web of Science ®Google Scholar
• Adiels M, Taskinen MR, Packard C, et al. Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia. 2006;49(4):755–765. doi:10.1007/s00125-005-0125-z
   PubMed Web of Science ®Google Scholar
• Stahl EP, Dhindsa DS, Lee SK, Sandesara PB, Chalasani NP, Sperling LS. Nonalcoholic fatty liver disease and the heart: JACC State-of-The-Art review. J Am Coll Cardiol. 2019;73(8):948–963. doi:10.1016/j.jacc.2018.11.050
   PubMed Web of Science ®Google Scholar
• Leung JC-F, Loong TC-W, Wei JL, et al. Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients. Hepatology. 2017;65(1):54–64. doi:10.1002/hep.28697
   PubMed Web of Science ®Google Scholar
• Zhao J, Fan H, Wang T, et al. TyG index is positively associated with risk of CHD and coronary atherosclerosis severity among NAFLD patients. Cardiovasc Diabetol. 2022;21(1):123. doi:10.1186/s12933-022-01548-y
   PubMed Web of Science ®Google Scholar
• Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43(6):1317–1325. doi:10.1002/hep.21178
   PubMed Web of Science ®Google Scholar
• Wai C-T, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38(2):518–526. doi:10.1053/jhep.2003.50346
   PubMed Web of Science ®Google Scholar
• Zhou W, Li S, Sun G, et al. Early warning of ischemic stroke based on Atherosclerosis Index combined with serum markers. J Clin Endocrinol Metab. 2022;107(7):1956–1964. doi:10.1210/clinem/dgac176
   PubMed Web of Science ®Google Scholar
• Dong B-Y, Mao Y-Q, Z-Y L, F-J Y. The value of the atherogenic index of plasma in non-obese people with non-alcoholic fatty liver disease: a secondary analysis based on a cross-sectional study. Lipids Health Dis. 2020;19(1):148. doi:10.1186/s12944-020-01319-2
   PubMed Web of Science ®Google Scholar
• Wang H, Gao P, Chen W, et al. A cross-sectional study of alcohol consumption and alcoholic liver disease in Beijing: based on 74,998 community residents. BMC Public Health. 2022;22(1):723. doi:10.1186/s12889-022-13175-z
   PubMed Web of Science ®Google Scholar
• X-y Y, Zhao Y, Song X-X, Song Z-Y. Association between non-alcoholic fatty liver disease and arterial stiffness in the non-obese, non-hypertensive, and non-diabetic young and middle-aged Chinese population. J Zhejiang Univ Sci B. 2014;15(10):879–887. doi:10.1631/jzus.B1400028
   PubMed Web of Science ®Google Scholar
• Shao C, Ye J, Li F, et al. Early predictors of cardiovascular disease risk in nonalcoholic fatty liver disease: non-obese versus obese patients. Dig Dis Sci. 2020;65(6):1850–1860. doi:10.1007/s10620-019-05926-7
   PubMed Web of Science ®Google Scholar
• Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol. 2010;55(13):1318–1327. doi:10.1016/j.jacc.2009.10.061
   PubMed Web of Science ®Google Scholar
• Diabetes Care. 10. Cardiovascular disease and risk management: standards of medical care in diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S111–S134. doi:10.2337/dc20-S010
   PubMedGoogle Scholar
• Buyadaa O, Magliano DJ, Salim A, Koye DN, Shaw JE. Risk of rapid kidney function decline, all-cause mortality, and major cardiovascular events in nonalbuminuric chronic kidney disease in type 2 diabetes. Diabetes Care. 2020;43(1):122–129. doi:10.2337/dc19-1438
   PubMed Web of Science ®Google Scholar
• Scirica BM, Mosenzon O, Bhatt DL, et al. Cardiovascular outcomes according to urinary albumin and kidney disease in patients with type 2 diabetes at high cardiovascular risk: observations from the SAVOR-TIMI 53 trial. JAMA Cardiol. 2018;3(2):155–163. doi:10.1001/jamacardio.2017.4228
   PubMed Web of Science ®Google Scholar
• Chang Y, Ryu S, Sung E, et al. Weight gain within the normal weight range predicts ultrasonographically detected fatty liver in healthy Korean men. Gut. 2009;58(10):1419–1425. doi:10.1136/gut.2008.161885
   PubMed Web of Science ®Google Scholar
• Wong VW-S, Wong GL-H, Chan RS-M, et al. Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease. J Hepatol. 2018;69(6):1349–1356. doi:10.1016/j.jhep.2018.08.011
   PubMed Web of Science ®Google Scholar
• Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature. 2001;414(6865):799–806. doi:10.1038/414799a
   PubMed Web of Science ®Google Scholar
• Bugianesi E, Gastaldelli A, Vanni E, et al. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia. 2005;48(4):634–642. doi:10.1007/s00125-005-1682-x
   PubMed Web of Science ®Google Scholar
• Huang J-F, Tsai P-C, Yeh M-L, et al. Risk stratification of non-alcoholic fatty liver disease across body mass index in a community basis. J Formos Med Assoc. 2020;119(1 Pt 1):89–96. doi:10.1016/j.jfma.2019.03.014
   PubMed Web of Science ®Google Scholar
• Kuchay MS, Martínez-Montoro JI, Choudhary NS, Fernández-García JC, Ramos-Molina B. Non-alcoholic fatty liver disease in lean and non-obese individuals: current and future challenges. Biomedicines. 2021;9(10):1346. doi:10.3390/biomedicines9101346
   PubMed Web of Science ®Google Scholar
• Softic S, Boucher J, Solheim MH, et al. Lipodystrophy due to adipose tissue-specific insulin receptor knockout results in progressive NAFLD. Diabetes. 2016;65(8):2187–2200. doi:10.2337/db16-0213
   PubMed Web of Science ®Google Scholar
• Bajaj M, Suraamornkul S, Pratipanawatr T, et al. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes. 2003;52(6):1364–1370. doi:10.2337/diabetes.52.6.1364
   PubMed Web of Science ®Google Scholar
• Gonzalez-Cantero J, Martin-Rodriguez JL, Gonzalez-Cantero A, Arrebola JP, Gonzalez-Calvin JL, Vinciguerra M. Insulin resistance in lean and overweight non-diabetic Caucasian adults: study of its relationship with liver triglyceride content, waist circumference and BMI. PLoS One. 2018;13(2):e0192663. doi:10.1371/journal.pone.0192663
   PubMed Web of Science ®Google Scholar
• Cai D, Yuan M, Frantz DF, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med. 2005;11(2):183–190. doi:10.1038/nm1166
   PubMed Web of Science ®Google Scholar
• Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62(1 Suppl):S47–S64. doi:10.1016/j.jhep.2014.12.012
   PubMed Web of Science ®Google Scholar
• Stefan N, Schick F, Häring H-U. Causes, characteristics, and consequences of metabolically unhealthy normal weight in humans. Cell Metab. 2017;26(2):292–300. doi:10.1016/j.cmet.2017.07.008
   PubMed Web of Science ®Google Scholar
• DeFilippis AP, Blaha MJ, Martin SS, et al. Nonalcoholic fatty liver disease and serum lipoproteins: the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis. 2013;227(2):429–436. doi:10.1016/j.atherosclerosis.2013.01.022
   PubMed Web of Science ®Google Scholar
• Feng R-N, Du -S-S, Wang C, et al. Lean-non-alcoholic fatty liver disease increases risk for metabolic disorders in a normal weight Chinese population. World J Gastroenterol. 2014;20(47):17932–17940. doi:10.3748/wjg.v20.i47.17932
   PubMed Web of Science ®Google Scholar
• Siddiqui MS, Fuchs M, Idowu MO, et al. Severity of nonalcoholic fatty liver disease and progression to cirrhosis are associated with atherogenic lipoprotein profile. Clin Gastroenterol Hepatol. 2015;13(5):1000–8.e3. doi:10.1016/j.cgh.2014.10.008
   PubMed Web of Science ®Google Scholar
• Pletcher MJ, Moran AE. Cardiovascular Risk Assessment. Med Clin North Am. 2017;101(4):673–688. doi:10.1016/j.mcna.2017.03.002
   PubMed Web of Science ®Google Scholar
• Tan MH, Johns D, Glazer NB. Pioglitazone reduces atherogenic index of plasma in patients with type 2 diabetes. Clin Chem. 2004;50(7):1184–1188. doi:10.1373/clinchem.2004.031757
   PubMed Web of Science ®Google Scholar
• Fernández-Macías JC, Ochoa-Martínez AC, Varela-Silva JA, Pérez-Maldonado IN. Atherogenic Index of plasma: novel predictive biomarker for cardiovascular illnesses. Arch Med Res. 2019;50(5):285–294. doi:10.1016/j.arcmed.2019.08.009
   PubMed Web of Science ®Google Scholar